Full Press Release Details
ReWalk Robotics Ltd. Appoints Ori Gon
as Chief Financial Officer
MARLBOROUGH, MA / YOKNEAM ILIT, ISRAEL-January 5, 2018
- ReWalk Robotics Ltd. ("ReWalk" or the "Company") (Nasdaq: RWLK) today announced the Company has
appointed its Corporate Controller, Ori Gon as Chief Financial Officer (CFO), effective February 22, 2018, succeeding Kevin Hershberger,
who has served as CFO since 2014. Mr. Hershberger is leaving to pursue an outside opportunity after putting in place and executing
on ReWalk's business strategies in collaboration with the Company's board and management team. Mr. Hershberger will
work closely with Mr. Gon to ensure a smooth and seamless transition.
"We are delighted to appoint Ori, who was originally hired
and groomed under Kevin's leadership and guidance, as ReWalk's new CFO. Ori
has a deep knowledge of our operating systems, experience in managing liquidity, and familiarity
with our markets, making him uniquely qualified to continue to seamlessly drive our financial strategy," said ReWalk
Mr. Gon, 36, has served as a Corporate Controller of the Company
since July 2015. Previously, he served as Controller at On Track Innovations, Ltd. from 2012 to 2015. He served as an Audit Manager
at KPMG from 2008 to 2012. Mr. Gon served as an officer in the Israeli Defense Forces from 2000 to 2004 and is now a captain in
the military reserve. Mr. Gon is a CPA and holds a B.A. in Economics from Hebrew University of Jerusalem.
for all of his many contributions to ReWalk. Kevin has been an integral part and a valuable member of ReWalk's management
team. Kevin was instrumental in establishing a solid financial reporting and controls infrastructure and building an experienced
and knowledgeable finance team, following ReWalk's IPO. For the past three years, he has led strategic funding and business
planning efforts to prepare ReWalk for long-term growth. We appreciate him staying on through the transition, and wish him the
best in his future endeavors," added Jasinski.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable
robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality of life for individuals
with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk
has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.
ReWalk is a registered trademark of ReWalk Robotics Ltd.
Forward-Looking Statements
In addition to historical
information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934.
Such forward-looking statements may include projections regarding ReWalk's future performance and, in some cases, may be
identified by words like "anticipate," "assume," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "future," "will," "should," "would,"
"seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's
current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many
of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially
from those indicated in the forward-looking statements include, among others: ReWalk's expectations regarding future growth,
including its ability to increase sales in its existing geographic markets, expand to new markets and achieve its planned expense
reductions; the conclusion of ReWalk's management for the financial statements for the third quarter of 2017 and for fiscal
2016, and the opinion of ReWalk's auditors in their report on the Company's financial statements for fiscal 2016, that
there are substantial doubts as to ReWalk's ability to continue as a going concern; ReWalk's ability to maintain and
grow its reputation and the market acceptance of its products; ReWalk's ability to achieve reimbursement from third-party
payors for its products; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's expectations
as to the results of, and the Food and Drug Administration's potential regulatory developments with respect to, ReWalk's
mandatory post-market 522 surveillance study; the outcome of ongoing shareholder class action litigation relating to ReWalk's
initial public offering; ReWalk's ability to repay its secured indebtedness; ReWalk's ability to improve its products
and develop new products; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation
of the intellectual property rights of others; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's
ability to secure capital from its equity and debt financings in light of limitations under its Form S-3, the price range of its
ordinary shares and conditions in the financial markets, and the risk that such financings may dilute ReWalk's shareholders
or restrict its business; ReWalk's ability to use effectively the proceeds of its offerings of its securities; ReWalk's
ability to maintain relationships with existing customers and develop relationships with new customers; the impact of the market
price of ReWalk's ordinary shares on the determination of whether ReWalk is a passive foreign investment company; ReWalk's
ability to comply with the continued listing requirements of the NASDAQ Capital Market and the risk that its ordinary shares will
be delisted if it cannot do so; ReWalk's compliance with medical device reporting regulations
to report adverse events involving its products and the potential impact of such adverse events on ReWalk's ability to market
and sell its products; and other factors discussed under the heading "Risk Factors" in ReWalk's Annual Report
on Form 10-K for the year ended December 31, 2016, as amended, filed with
the U.S. Securities and Exchange Commission and other documents subsequently
filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking
statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual
results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict
all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether
as a result of new information, future developments or otherwise.
In-Site Communications, Inc.